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Abstract 
Background and propose: Changes in DNA methylation are associated with changes in somatic cell fate without 
the alteration of coding sequences. In addition to its use as a traceable biomarker, reversible DNA methylation could 
also serve as a therapeutic target. In particular, if the development of drug resistance is associated with changes in 
DNA methylation, then demethylation might reverse the resistance phenotype. The reversion of the drug‑resistance 
might then be feasible if the association between abnormal DNA methylation and the development of drug‑resist‑
ance could be identified.
Methods: Methylation differences between the drug‑resistance cervical cancer cell, SiHa, and its derived oxaliplatin‑
resistant S3 cells were detected by methylation specific microarray. The drug‑resistance cells were treated with 
demethylation agent to see if the resistance phenotype were reversed. Targeted methylation of one of the identified 
locus in normal cell is expected to recapitulate the development of resistance and a two‑component reporter system 
is adopted to monitor the increase of DNA methylation in live cells.
Results: In this report, we identified methylation changes, both genome‑wide and within individual loci, in the 
oxaliplatin‑resistant cervical cancer cell S3 compared with its parental cell line SiHa. Treatment of S3 with a demethyla‑
tion agent reversed increases in methylation and allowed the expression of methylation‑silenced genes. Treatment 
with the demethylation agent also restored the sensitivity of S3 to cisplatin, taxol, and oxaliplatin to the same level as 
that of SiHa. Finally, we found that methylation of the target gene Casp8AP2 is sufficient to increase drug resistance in 
different cells.
Conclusions: These results suggest that global methylation is associated with the development of drug resistance 
and could serve as a biomarker and therapeutic target for drug resistance in cervical cancer.
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Background
DNA methylation is a stable, dominant, and inheritable 
epigenetic modification that silences genes in somatic 
cells [1–3]. Through DNA methylation, environmen-
tal factors such as growth factors, food, and toxins can 
reshape the methylome and eventually differentiate 
or transform a cell [4, 5]. For example, knockdown of 
upstream estrogen receptors (ERs) increases methylation 
within ER target genes [6]. Also, various concentrations 
of diets given to pregnant mice can lead to production 
of the methylation source S-adenosylmethionine (SAM), 
altering methylation level at the promoter regions of fur 
color reporter genes and causing variegated fur color in 
the offspring [7–9]. Furthermore, environmental toxins 
such as endocrine disrupters can change methylation 
states through different signaling pathways [10, 11]. All of 
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these examples demonstrate that the methylome is sub-
ject to further modifications.
Changes in the methylome are associated with cellular 
transformation [2, 12–14]. Dramatic methylome changes 
can be initiated early during the production of germ line 
cells and even before implantation [15, 16]. Particular 
changes of the methylome are associated with the speci-
fication of different cell lineages during development 
[17, 18]. Deviating from a normal state, abnormal global 
hypomethylation or hypermethylation of tumor suppres-
sor genes can induce cancer as revealed by genetic studies 
[19, 20]. The accumulation of abnormal DNA methyla-
tion can be found after tumor formation, metastasis, and 
the development of drug resistance, although it’s not easy 
to form connections between particular changes in meth-
ylation and specific transformation events [21].
Several changes in DNA methylation may affect cellu-
lar sensitivity to drug treatment. For example, increased 
DNA methylation within BRCA1 promoter in ovarian 
cancer patients correlate with better platinum-based 
chemotherapy [22]. By contrast, hypermethylation of 
MLH1 is associated with increased cisplatin resistance 
in an ovarian cancer cell line [23]. Also, hypermeth-
ylated DAPK in colon and breast cancers correlates 
with drug resistance [24, 25]. DAPK works through the 
tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL). Hypermethylation within the TRAIL gene cor-
relates with drug resistance in lung cancer [26], and the 
reversal of TRAIL methylation by methylation inhibitor 
treatment restores sensitivity to drug treatment [27–29]. 
These findings suggest that abnormal DNA methylation 
might affect cell death pathways and the development of 
drug resistance in cancer [30, 31].
Identifying the methylation changes related to drug 
resistance might provide a diagnostic clue as to whether 
the development of drug resistance is methylation-
dependent. Also, if changes in DNA methylation are 
sufficient to cause drug resistance in cancer, then the 
reversal of these changes might restore the sensitiv-
ity of cancer cells to drug treatment. In this report, we 
characterized the SiHa cancer cell-derived oxaliplatin-
resistant cervical cancer cell line S3 [32]. Treatment with 
a methylation inhibitor reversed drug resistance, indicat-
ing that the development of resistance is methylation-
dependent [33]. Differential methylation hybridization 
(DMH) microarray was performed to detect methylation 
changes associated with the development of drug resist-
ance [34, 35]. Previously, demethylation of these target 
loci restored the expression of the target genes and their 
sensitivities to different cancer drugs [36–39]. Finally, we 
applied a two-component system to monitor DNA meth-
ylation of the identified target gene [17, 40] Casp8AP2 
(NM_001137667) and found that increased methylation 
was associated with a drug-resistant phenotype. These 
findings suggest the possibility of identifying changes in 
methylation that are related to drug resistance in cancer.
Methods
Cell culture, isolation, and characterization
Human mesenchymal stem cells (MSCs) were iso-
lated and cultured as described by Lee et  al. [41], and 
cell expansion was as described by Hsiao et  al. [17, 41]. 
MDA-MB-231, SiHa, and S3 cells were cultured with 
L-15, Minimum Essential Medium (MEM; Invitrogen), 
and MEM with 2  μg/ml oxaliplatin, respectively. For 
all cells, the medium was supplemented with 10 % fetal 
bovine serum (Invitrogen), 100 mg/ml penicillin/strepto-
mycin (Invitrogen), and 2 mM l-glutamine (Invitrogen).
5‑Aza‑2′‑deoxycytidine (5‑Aza) treatment
Cells were treated with 5 μM 5-aza or an equal volume of 
DMSO as a control for 5 consecutive days.
Cloning of the human Casp8AP2 promoter
Primers for the human Casp8AP2 promoter are listed in 
Additional file  1: Table  S1. Human MSC genomic DNA 
was used as a polymerase chain reaction (PCR) template. 
Purified PCR products were ligated into the pyT&A clon-
ing vector (Yeastern Biotech) according to the manufac-
turer’s protocol. Inserts were confirmed by restrictions 
and sequencing.
In vitro DNA methylation
PCR-amplified Casp8AP2 promoters (4  μg) were incu-
bated with 20 units of CpG methyltransferase (New Eng-
land BioLabs) at 37 °C for 4 h in the presence of 160 μM 
SAM to induce methylation.
Validation of in vitro DNA methylation
Methylated DNA showing resistance to methylation-sen-
sitive restriction enzymes (HpaII) was considered to indi-
cate completed conversion (Additional file 1: Figure S1).
Transfection of methylated DNA
PCR products (0.4  μg/well, unmethylated as a con-
trol) were denatured at 95  °C and then transfected into 
5 × 105 cells/well in a 6-well plate using DMRIE-C (Inv-
itrogen) according to the manufacturer’s instructions. 
Cells were transfected three times, on day 1, 3, and 5 [17, 
42]. The transfection efficiency and the localization of 
the transfected DNA were tracked as in Additional file 1: 
Figure S2.
Bisulfite conversion
Genomic DNA (0.5 μg) was bisulfite-converted and puri-
fied as described by Yan et al. [43].
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Semi‑quantitative real‑time methylation‑specific PCR 
(qMSP)
The qMSP was performed as described by Yan et al. [43]. 
Bisulfite-converted genomic DNA was subject to real-
time PCR with methylation-specific primers (Additional 
file 1: Table S1). A SYBR Green I PCR Kit (Toyobo) was 
used to conduct qMSP in an iQ5 PCR instrument (Bio-
Rad). After reactions, analysis of melting temperature 
was performed to ensure that a specific amplicon was 
generated. Col2A1 (NM_033150) was used for standard 
curve construction and as a loading control. Methyla-
tion percentage was calculated as: (mean of target gene)/
(mean of Col2A1). Fold change was calculated as: (tar-
geted DNA methylation percentage)/(mock methylation 
percentage).
Differential methylation hybridization microarray, DMH
The DMH procedure was performed as described by 
Leu et al. [44] using a human CpG microarray (Agilent). 
Treated and control genomic DNA (2 μg) was restricted 
into small fragments by MseI and ligated with desig-
nated primers. Methylation-sensitive restriction enzymes 
(BstUI and HpaII) were used to discriminate between 
methylated and unmethylated DNAs, and DNAs was 
then amplified by PCR using adaptors as primers. PCR-
amplified DNA from mock-treated S3 cells was labeled 
with Cy5 and from SiHa or 5-aza-treated S3 cells was 
labeled with Cy3 and then co-hybridized onto slides. 
After scanning, the ratio between Cy5 and Cy3 dyes was 
normalized by locally weighted scatterplot smoothing. 
Significant methylation differences were identified.
Semi‑quantitative RT‑PCR (qRT‑PCR)
RNA isolation, first-strand cDNA synthesis, and detec-
tion of transcripts were carried out as previously 
described [44]. Total RNA (2 μg) was reverse transcribed 
using SuperScript II reverse transcriptase (Invitrogen). 
qRT-PCR was performed using a SYBR Green I PCR Kit 
(Toyobo) in an iQ5 Real-Time instrument (Bio-Rad). A 
serial dilution of GADPH-amplified (NM_002046) cDNA 
was used as a control to generate a standard curve, and 
GAPDH from each sample was used as a loading control. 
The primers used are listed in Additional file 1: Table S1.
Cell survival assay
Cells (5  ×  104) were plated into each well of a 96-well 
assay plate and allowed to attach. Cells were then treated 
with different concentrations of drugs and incubated at 
37  °C overnight. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) solution (20  μl, 5  mg/
ml; Sigma) was added to each well and incubated at 37 °C 
for 5  h. The reaction was terminated by adding 100  μl 
DMSO, and absorbance was measured at 595 nm.
Western blot analysis
Cells were harvested in RIPA buffer, and proteins were 
separated in 10  % polyacrylamide gel and trans-blotted 
onto a membrane. After blocking with skim milk, the 
membrane was hybridized with designated antibod-
ies. After washing, secondary antibody conjugated with 
horseradish peroxidase was used to detect hybridization. 
Results were visualized by chemiluminescence. The film 
was then scanned and analyzed.
Immunostaining
Treated or control cells (5 × 104) were plated into 4-well 
chamber slides and allowed to attach. After washing and 
fixing in 2 % formaldehyde, cells were again washed and 
permeabilized by 0.5  % NP40 in phosphate-buffered 
saline (PBS). After another wash, horse serum in PBS 
(1:100) was used to block, and the slides were washed. 
Specific antibodies were used to stain the cells, and flu-
orescein-conjugated secondary antibodies were used to 
detect the staining. The slides were mounted, and cells 
were visualized using a fluorescent microscope.
Enzyme‑linked immunosorbent assay (ELISA)
Green fluorescent protein (GFP) ELISA was performed 
using an ELISA Kit (Cell Biolabs) according to the man-
ufacturer’s instructions. Starting from 2 ×  104 cells per 
assay, the cells were harvested and lysed, and the col-
lected proteins were quantified. Proteins (0.1 μg/ml per 
assay) were compared with the provided standard after 
binding to GFP antibody, secondary antibody, and sub-
strate solution with vigorous washes between steps. 
After stopping the reaction, absorbance was measured at 
595 nm.
Results
Changes in DNA methylation and expression 
in oxaliplatin‑resistant cervical cancer S3 cells
A more than 40-fold decline in sensitivity was found 
for the oxaliplatin-resistant cervical cancer cell S3 com-
pared with its parental SiHa cervical cancer cell line 
(Fig.  1a). The expression of several death-related genes 
decreased during the development of oxaliplatin resist-
ance (Fig.  1b). This decreased expression of death-
related genes, such as Casp8AP2, the detoxification gene 
GSTp1, and the repair gene MLH1, was associated with 
increased methylation within their promoter regions 
(Fig.  1c). These findings suggest that changes in epi-
genetic and DNA expression states are involved in the 
development of drug resistance.
Global methylation changes in S3 cells
Genome-wide changes in methylation during the devel-
opment of drug resistance in S3 cells were detected by 
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DMH. Changes in methylation were compared between 
S3 and SiHa cells (Fig. 2a, S1 and S2) as well as before 
and after 5-aza treatment in S3 cells (Fig.  2a, S3 and 
S4). After hierarchical clustering analysis of repeated 
DMH results, we found both increases (Fig. 2a, block I) 
and decreases (Fig. 2a, block III) in methylation within 
the S3 genome. Some of the increases in methylation 
were inhibited by 5-aza treatment (block I), suggest-
ing that these methylation changes are associated with 
the development of drug resistance. On the other hand, 
some increases in DNA methylation were observed after 
5-aza treatment (block III), suggesting that these meth-
ylation changes are not involved in the development of 
drug resistance. Three primary target loci (NEUROG2, 
PVT1, and DLX2) identified from DMH analysis were 
validated together with the three known targets (Cas-
p8AP2, GSTP1, and MLH1) as controls (Fig.  2b). S3 
showed increased methylation within the promoter 
region and lower expression of these genes compared 
with SiHa. This increased methylation (Fig.  2c, upper 
panel) and lower gene expression (Fig. 2c, lower) in S3 
cells was reversed by 5-aza treatment. Treatment with 
5-aza also increased Casp8AP2 expression in S3 cells 
as detected by RT-PCR (Fig.  2c) and immunostaining 
(Fig. 2d, also detected by Western blot, Additional file 1: 
Figure S3).
Demethylation and reversal of drug resistance in S3
If increased DNA methylation in drug-resistant can-
cer cells is necessary for the maintenance of drug 
resistance, then the reversal of DNA methylation in 
S3 should restore their sensitivity to drug treatment. 
After 5-aza treatment, S3 lost their resistance to cispl-
atin and taxol (Fig. 3a, upper and lower panels, respec-
tively). Also, after 5-aza treatment, the sensitivity of 
S3 cells to oxaliplatin was restored to the same level as 
that in untreated SiHa (Fig.  3b). Together, these find-
ings indicate that the maintenance of methylation may 
be critical for the maintenance of drug resistance in 
cancer cells.
Fig. 1 Gene methylation and expression changes in S3 cells. a Survival of S3 and SiHa cells upon treatment with different concentrations of oxali‑
platin as assessed by MTT assay. b Differences in gene expression between S3 and SiHa cells as revealed by protein levels in western blot analysis. c 
Differences in gene methylation and expression between S3 and SiHa cells. Methylation within the promoter regions (arrowheads) was measured 
by qMSP (upper panels). Corresponding changes in gene expression were detected by qRT‑PCR (lower panel)
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Visualization of the targeted Casp8AP2 methylation 
and increased drug resistance in cells
To confirm that methylation of specific genes is sufficient 
to increase cellular drug resistance, we developed a two-
component system to monitor methylated Casp8AP2. To 
visualize the targeted methylation of Casp8AP2, the Cas-
p8AP2 promoter was cloned in front of the Tet repres-
sor gene, and, on another vecor, Tet repressor binding 
sites TetO2 (Tet operator) were cloned in front of the 
enhanced GFP (EGFP) reporter (Fig. 4a). If Casp8AP2 is 
not methylated, the Tet repressor is expressed, binds to 
TetO2 and suppresses EGFP expression. By contrast, the 
targeted methylation of Casp8AP2 suppresses Tet repres-
sor gene expression and releases the suppression of EGFP 
expression. Using this system, Casp8AP2 methylation is 
reflected by increased levels of EGFP.
We chose both an upstream and downstream regions 
to targeted methylate Casp8AP2 (Fig.  4b, upper panel). 
We observed increases in Casp8AP2 methylation (Fig. 4b, 
center panel) and EGFP expression (Fig. 4b, lower panels) 
regardless of whether the far or near ends were targeted. 
The targeted CAsp8AP2 methylation was also evidenced 
Fig. 2 Global methylation changes in S3 cells. a DMH microarray detected differences in genome‑wide methylation between S3 and SiHa cells 
(S1 and S2) and between 5‑aza‑treated and ‑untreated S3 cells (S3 and S4). These four sets of data were then subject to unsupervised hierarchical 
clustering analysis. Blocks I, II, and III designate the main clustering blocks. b Validation of gene methylation and expression differences between S3 
and SiHa cells. Three genes (NEUROG2, PVT1, and DLX2) with identified methylation differences from a were validated by qMSP, and changes in their 
expression were detected by qRT‑PCR. Three genes (Casp8AP2, GSTP1, and MLH1) with known methylation and expression differences between 
S3 and SiHa cells were used as controls. c These loci were hypermethylated in S3 cells, and their methylation was reversed (upper panel) and their 
expression restored (lower panel) by treatment with 5‑aza. d Immunostaining confirmed the restoration of Casp8AP2 expression after treatment 
with 5‑aza
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by bisulfite sequencing (Additional file 1: Figure S4) Suc-
cessful targeted DNA methylation increased the methyla-
tion (Fig. 4c, upper panels) and reduced gene expression 
(Fig.  4c, lower panels) of Casp8AP2 in both MSCs and 
the breast cancer cell line MDA-MB-231. Both cell lines 
became less sensitive to cisplatin and taxol after Cas-
p8AP2 methylation (MDA-MB-231 cells: Fig. 4d; MSCs: 
Additional file 1: Figure S5).
Discussion
DNA methylation is an inheritable mark that could 
direct gene expression and cell fates [45, 46]. Changes 
in DNA methylation often imply a detour in cell physi-
ology and could serve as a way to further vary cellular 
transformation and clonal expansion [47, 48]. Accu-
mulating data correlates abnormal DNA methylation 
with tumorigenesis, metastasis, and the development 
of drug resistance [47, 49]. Although genetic stud-
ies directly link abnormal DNA methylation to cellu-
lar transformation, how abnormal DNA methylation 
leads to the development of drug resistance is relatively 
unclear.
DNA methylation is a stable change, yet it is also 
reversible like other epigenetic modifications. Its stabil-
ity makes methylation easy to detect, and its reversibility 
makes it a possible therapeutic target [50, 51]. If methyl-
ation of a specific locus is sufficient to cause drug resist-
ance, then detection of this modification might be used 
to monitor the development of drug resistance. Further-
more, if demethylation of a locus is closely related to the 
reversal of drug resistance, then it could be a candidate 
mechanism for restoring the sensitivity of cells to drug 
treatment. Therefore, we used DMH to identify several 
methylation changes occurring during the development 
of drug resistance. The loci that became hypermethyl-
ated and that showed a reversal of methylation after 
treatment with a demethylation agent could be primary 
targets [52].
In the present study, by establishing a two-com-
ponent system for monitoring targeted DNA meth-
ylation and quantifying the degree of methylation, we 
found that targeted Casp8AP2 methylation caused the 
development of cellular drug resistance in different 
lines of cells. This monitoring system could be further 
used to monitor environmentally induced changes in 
methylation state and to track targeted cells in their 
microenvironments.
Conclusion
Global methylation changes are associated with the 
development of drug resistance in cervical cancer. Meth-
ylation inhibitors reverse the resistance-associated 
methylation increases and the resistance phenotype. 
Methylation changes might serve as a biomarker and 
therapeutic target for drug resistance in cervical carci-
noma cells.
Fig. 3 5‑Aza treatment reverses drug resistance in S3 cells. a After 
S3 cells were mock‑treated or treated with 5‑aza, they were treated 
with different concentrations of cisplatin (upper panel) or taxol (lower 
panel). Mock‑treated SiHa cells were used as a control. Cell survival 
was measured by MTT assay. b S3 and SiHa cells were treated with 
5‑aza to demethylate their DNA, and cells were then challenged with 
different concentrations of oxaliplatin. Cell survival was measured 
by MTT assay. The survival rates of untreated S3 and SiHa cells were 
included from Fig. 1 for comparison
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